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ABSTRACT
Objective To investigate the determinants of impaired
spinal and hip mobility in patients with early axial
spondyloarthritis (axSpA).
Methods Five-year longitudinal data from the DEvenir des
Spondyloarthrites Indifférenciées Récentes (DESIR) cohort
were analysed. Associations were investigated using
generalised estimating equations, using Bath Ankylosing
Spondylitis Metrology Index (BASMI) linear or each of the
five components of BASMI as dependent variables, and
clinical and demographic variables as independent variables
in univariable models. Multivariable analyses were
performed, adjusting for potential confounders.
Results Data from 644 patients and 5152 visits were
analysed. Higher BASMI values were independently and
positively associated with Ankylosing Spondylitis Disease
Activity Score C reactive protein (ASDAS-CRP) (adjusted
B (adjB)=0.21; 95% CI=0.15 to 0.28), MRI spinal
inflammation score (adjB=0.11; 95% CI=0.04 to 0.19),
enthesitis score (adjB=0.02; 95% CI=0.01 to 0.04) and age
(adjB=0.02; 95% CI=0.01 to 0.03). All BASMI components
were independently associated with ASDAS-CRP and MRI
spinal inflammation, except for maximal intermalleolar
distance (reflecting hip mobility), which was not associated
with MRI spinal inflammation.
Conclusion In early axSpA, spinal mobility impairment is
independently determined by clinical disease activity, MRI
spinal inflammation, enthesitis and age. The influence of
spinal inflammation prevails in early axSpA, as opposed to
spinal structural damage, which may become more relevant
in later disease stages.
INTRODUCTION
Classical hallmarks of axial spondyloarthritis
(axSpA) are chronic back pain, stiffness and
impairment of spinal and hip mobility. The
Assessment in SpondyloArthritis interna-
tional Society (ASAS) recommends spinal
mobility as a core domain in both clinical
practice and trials,1 and the European Medi-
cines Agency states that ‘spinal mobility is of
great importance in axSpA and constitutes
the most organ specific domain’, spinal mobi-
lity ‘is considered an important measure to
assess efficacy’ and ‘imaging methods should
be supported by a demonstration of an effect
on the clinical consequences of the slowing or
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What is already known about this subject?
► Spinal mobility is a core domain of axial
spondyloarthritis (axSpA) assessment.
► Spinal mobility is a complex outcome, which is highly
influenced by clinical and individual factors.
► In radiographic axSpA, spinal mobility impairment is
independently determined by irreversible spinal
structural damage and reversible spinal
inflammation.
What does this study add?
► In early axSpA, spinal mobility impairment is
independently determined by clinical disease
activity, MRI spinal inflammation, enthesitis and age.
► In the early stages of axSpA, disease activity and
spinal inflammation seem to play a more relevant
role than structural damage on mobility.
► Clinical disease activity, enthesitis and spinal
inflammation are critical factors influencing mobility
—they complement each other and they are all
amenable to treatment.
How might this impact on clinical practice?
► The multifactorial aspects of spinal and hip mobility
need to be taken into account when interpreting
absolute and change mobility scores.
► Early treatment of clinical symptoms, enthesitis and
reversible spinal inflammation may be of great
importance in recovering mobility and achieving
better patient outcomes.
► This study supports the widespread use of ASDAS, as
this index showed a good association with all BASMI
components, therefore further validating this
measure.
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prevention of the structural damage (i.e. an effect on
spinal mobility)’.2 It is therefore of utmost importance
to understand the factors that influence spinal (and hip)
mobility in axSpA.
Spinal mobility has been more extensively studied in
patients with axSpA with long-standing disease compared
with patients at earlier disease stages. Nevertheless, recent
evidence points to the presence of significant mobility
impairment even in early disease.3 Furthermore, the
axSpA disease spectrum should be understood as
a whole, and the study of the determinants of mobility
in earlier disease stages will promote a better knowledge
of the disease itself, as it is likely that the relative contribu-
tion of factors associated with spinal mobility in axSpA
will change over time.
It has been shown that spinal mobility impairment is
independently determined both by irreversible spinal
damage and by reversible spinal inflammation. However,
as mentioned earlier, these relationships have been inves-
tigated mainly in patients with longstanding disease
(ankylosing spondylitis (AS)) and at the cross-sectional
level only. Moreover, only the composite score Bath Anky-
losing Spondylitis Metrology Index (BASMI) has been
evaluated rather than individual components of BASMI
(tragus-to-wall distance, cervical rotation, anterior lum-
bar flexion, lateral spinal flexion and maximal intermal-
leolar distance).4 5
Our aim was to investigate the determinants of
impaired spinal and hip mobility in patients with early
axSpA.
METHODS
We analysed longitudinal data from the DEvenir des
Spondyloarthrites Indifférenciées Récentes (DESIR)
cohort, collected during the first 5 years of follow-up.
This is a prospective observational cohort of patients
aged 18–50 years with recent onset (>3 months,
<3 years) inflammatory back pain (Calin or the Berlin
criteria), suggestive of axSpA (level of confidence ≥5/
10), as previously described.6 We selected patients
with a definite diagnosis of axSpA according to the
treating rheumatologist, at the end of follow-up
(month 60).
Mobility was assessed using the linear definition of
BASMI (range 0–10, with higher scores reflecting worse
mobility), and using the individual components of
BASMI: tragus-to-wall distance (cm), cervical rotation
(degrees), anterior lumbar flexion (modified
Schöber; cm), lateral spinal flexion (cm) and maximal
intermalleolar distance (cm).7–9 Disease activity was mea-
sured using the AS Disease Activity Score C reactive pro-
tein (ASDAS-CRP), a composite index that incorporates
the assessment of four different domains (back pain,
duration of morning stiffness, global assessment of dis-
ease activity, peripheral pain/swelling), scored on a 0–10
numeric rating scale by patients, plus an inflammatory
marker (CRP).10–12 The concise Mander Enthesitis Score
(cMES) with gradation was used to evaluate enthesitis
involvement. This score considers 13 entheseal sites cor-
responding to mainly axial locations: left and right first
costochondral joint, left and right seventh costochondral
joint, left and right posterior superior iliac spine, left and
right anterior superior iliac spine, left and right iliac
crest, left and right proximal insertion of Achilles tendon
and fifth lumbar spinous process. Each one of the sites is
graded from 0 to 3 (0=no pain; 1=mild tenderness;
2=moderate tenderness; 3=wince or withdraw), the total
range being from 0 to 39.13 The following entheseal sites
(N=7) were arbitrarily defined as ‘pure axial sites’ for the
purpose of sensitivity analyses: left and right first costo-
chondral joint, left and right seventh costochondral
joint, left and right posterior superior iliac spine and
fifth lumbar spinous process. Spinal MRI inflammation
and sacroiliac joint (SIJ) MRI inflammation were
assessed using the Berlin scoring system and the Spondy-
loarthritis Research Consortium of Canada (SPARCC)
scoring system, respectively; spinal and hip radiographic
structural damage were assessed using the modified
Stoke AS Spinal Score (mSASSS)9 and the Bath Ankylos-
ing Spondylitis Radiology Index for the hips (BASRI-
hips; the mean score of both hips was used in the present
study),14 respectively. Treatment with nonsteroidal anti-
inflammatory drugs (NSAID), conventional disease-
modifying antirheumatic drugs (cDMARD) and anti-
tumour necrosis factor (anti-TNF) drugs were assessed
according to their intake in the 6 months before each
visit (yes or no).
Associations were tested using generalised estimating
equations, a multilevel approach that uses all available
data during follow-up, while taking into account missing
values, and adjusting for within-patient correlation.15
Only observed data were used, imputation was not per-
formed. The BASMI total score or the individual mea-
surements of the BASMI components were used as
dependent variables, and clinical and demographic vari-
ables (age; gender; level of education; body mass index
(BMI); human leucocyte antigen B27 (HLA-B27) status;
symptom duration; employment status; smoking status;
presence of current peripheral arthritis; enthesitis score;
ASDAS-CRP; mSASSS; BASRI-hips; total Berlin score of
the spine; total SPARCC score of the SIJs; and NSAID,
cDMARD and anti-TNF intake in the last 6 months) were
used as independent variables in univariable models. The
BASRI-hips was only used to test associations with the
BASMI total score and with maximal intermalleolar dis-
tance. As physical function and quality of life are health
domains considered to be hierarchically superior to
spinal mobility, they were not included in the analyses.4
Multivariable models were then performed, adjusting for
potential confounding factors. Variables with a p value
<0.05 were retested in those multivariable models. Six
models were built, one regarding the BASMI and five
regarding the individual components of BASMI.
A sensitivity analysis using purely axial entheseal sites
was performed.
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From the 708 patients enrolled in the DESIR cohort, we
excluded 64 from our analysis as they did not have
a definite clinical diagnosis of axSpA at month 60. Data
from 644 patients and 5152 visits collected during
60 months were analysed (online supplemental table 1).
This was a young and early disease cohort (mean age 33.6
(±8.6) years; mean symptom duration 1.5 (±0.9) years)
comprising 303 male patients (47.0%) with a very low
level of structural damage at baseline (mean mSASSS
0.4 (±1.6) units). Mean BASMI at baseline was 2.4
(±1.0), reflecting an overall low level of mobility impair-
ment. At month 60, only 113 (17.5%) of the patients had
a diagnosis of AS (ie, radiographic axSpA).
In the univariable analysis, male gender, education (uni-
versity or equivalent), higher BMI and HLA-B27 positivity
were associated with better mobility as assessed by BASMI.
Conversely, older age, higher ASDAS-CRP, enthesitis
score, mSASSS, spinal MRI Berlin score, BASRI-hips
score and NSAID intake in the last 6 months were asso-
ciated with poorer mobility (table 1). Regarding the indi-
vidual components of BASMI, significant associations with
clinical and imaging variables are also presented in table 1.
Online supplemental table 2 presents the results of all
univariable analysis, either significant or non-significant.
In the multivariable analyses (table 2), we found an
independent association between higher BASMI values
(worse mobility) and age (adjusted B (adjB)=0.02; 95%
CI=0.01 to 0.03), ASDAS-CRP (adjB=0.21; 95%CI=0.15 to
0.28), enthesitis score (adjB=0.02; 95% CI=0.01 to 0.04),
BASRI-hips (adjB=0.65; 95% CI=0.31 to 1.00) and MRI
spinal inflammation score (adjB=0.11; 95% CI=0.04 to
0.19). Better mobility measured by BASMI was associated
with BMI (adjB=−0.04; 95% CI=−0.06 to −0.01) and HLA-
B27 positivity (adjB=−0.24; 95% CI=−0.41 to −0.08).
Disease activity measured by ASDAS-CRP was indepen-
dently associated with all individual BASMI components,
and this index was the only variable that kept its signifi-
cance along the multivariable models for each one of the
BASMI components. Apart from maximal intermalleolar
distance (a measure of hip mobility), all other individual
mobility measures (measures of spinal mobility) were
associated with MRI spinal inflammation. mSASSS was
only associated with lateral spinal flexion and was a (non-
significant) contributory factor to tragus-to-wall distance
and cervical rotation. Other variables presenting consis-
tent and significant associations across spinal and hip
mobility measures were age and enthesitis score (both
influencing 4/6 mobility measures), followed by gender,
BMI, HLA-B27 positivity and symptom duration (all influ-
encing 3/6 mobility measures) (figure 1).
A sensitivity analysis performed using the enthesitis
score limited to purely axial entheseal sites yielded similar
results (online supplemental table 3) for BASMI, cervical
rotation and maximal intermalleolar distance. However,
the association with lateral spinal flexion was lost (and
similarly to the main model; it was associated neither with
tragus-to-wall distance nor with anterior lumbar flexion).
In addition, the best-fit model formaximal intermalleolar
distance now included BASRI-hips as a variable with
a significant association with this mobility measure.
DISCUSSION
This study provides evidence of a consistent and indepen-
dent association between disease activity measured by
ASDAS-CRP and multiple spinal and hip mobility mea-
sures in an early axSpA cohort with low levels of spinal
structural damage. Moreover, inflammation measured by
MRI was a key determinant of spinal mobility. Maximal
intermalleolar distance (a measure of hip mobility) was
the only measure not associated with MRI spinal inflam-
mation. More severe enthesitis and older age also showed
consistent and independent associations with worse
mobility.
In late-stage disease, the importance of spinal inflam-
mation along with structural damage for spinal mobility
had already been established, at the cross-sectional
level.4 5 16 17 However, in early disease stages, given
the low levels of structural damage, spinal structural
damage may not be the main factor determining mobi-
lity impairment, and our results point to a more impor-
tant role of clinical disease activity, enthesitis and MRI
inflammation in determining spinal and hip mobility
impairment. The importance of spinal inflammation in
early disease had already been suggested in patients
with AS who had less than 3 years of disease,5 and
recently in patients with early axSpA with a mean dura-
tion of back pain inferior to 1 year.3
Mobility had already been described as independently
associated with ASDAS-CRP and age in early3 and late
disease.18 Even in healthy population, mobility tends to
decrease with age. This observation led to the creation of
reference intervals for mobility measures, which take into
account the individual’s age and height.19 To our knowl-
edge, this is the first study reporting an association
between lower enthesitis scores and better mobility. As
cMES evaluates several entheseal sites in relation with
spinal and hip movement, the inflammatory process in
the entheses might be leading to pain and local damage
of the entheses and associated tendons, which would
subsequently contribute to the impairment of spinal and
hip mobility. The contribution of peripheral arthritis to
tragus-to-wall distance and cervical rotation may suggest
that the overall disease inflammatory state plays a role on
spinal mobility through the inflammation of several other
structures not specifically assessed in this study.
All clinical and imaging variables had consistent asso-
ciations with each one of the five individual BASMI com-
ponents, apart for less consistent associations seen with
gender, symptom duration and BMI. In axSpA, women
tend to present higher disease activity levels and higher
involvement of peripheral joints,20 21 while spinal mobi-
lity tends to be better in women compared to men.21 22 In
our study, being amen was independently associated with
better lateral spinal flexion and maximal intermalleolar
Spondyloarthritis
Carvalho PD, et al. RMD Open 2020;6:e001356. doi:10.1136/rmdopen-2020-001356 3
copyright.
 on F












pen: first published as 10.1136/rm





distance, while tragus-to-wall distance was worse in men
compared to women. A recent cross-sectional study aim-
ing to explore the differences regarding mobility in sev-
eral subgroups of patients with axSpA concluded that
gender might not have a major impact in the majority of
BASMI components.23 These findings are in accordance
with the absence of gender-specific reference intervals for
the definition of normal spinal mobility measures.19 In
another study performed with the DESIR cohort, HLA-
B27 was associated with axial inflammation, less delay in
diagnosis and decreased disease activity measured either
by ASDAS-CRP or Bath Ankylosing Spondylitis Disease
Activity Index.24 An earlier diagnosis prompted by HLA-
B27 and consequently earlier treatment and lower disease
activity may be mediating the observed association
between HLA-B27 and some of the mobility scores in
our study. A higher level of education has been described
as being associated with lower disease activity states in
SpA25 and also in rheumatoid arthritis,26 which again
may be mediating the observed association between
higher level of education and some of the mobility scores
in our study. More educated people may also
Table 1 Univariable GEE results (B; 95%CI) presenting significant associations* between BASMI linear (or its components) and
clinical and demographic variables
Mobility measures where higher
























































































































the last 6 months
−2.04
(−3.67 to −0.40)
*Only associations with a p value<0.05 are presented (for the full set of univariable results, see online supplemental table 2).
†Education at baseline (university or equivalent).
‡BASRI-hips was only considered for BASMI linear and for maximal intermalleolar distance.
ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score C reactive protein; BASMI, Bath Ankylosing Spondylitis Metrology Index; BASRI-
hips, Bath Ankylosing Spondylitis Radiology Index for the hips; BMI, bodymass index; cDMARD, conventional disease-modifying antirheumatic
drugs; GEE, generalised estimating equations; HLA-B27, human leucocyte antigen B27; mSASSS, Modified Stoke Ankylosing Spondylitis
Spinal Score; NSAID, nonsteroidal anti-inflammatory drugs; SIJ, sacroiliac joint.
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hypothetically have a better understanding of the condi-
tion and engage with exercise programmes that may con-
tribute to better mobility. Interestingly, mobility had
already been reported as being associated with employ-
ment status,27 an association that might simply be reflect-
ing the fact that patients with better mobility are more
likely to retain their jobs, especially in the context of
physically demanding jobs. The absence of a consistent
association between mobility and symptom duration may
be related to the early disease profile of these patients.
However, disease duration may have a more significant
impact on mobility in late disease.23 Structural damage
to the hips was independently associated with worse
BASMI but not with maximal intermalleolar distance
(non-significant association but numerically in the same
direction as with BASMI). However, in the sensitivity
analysis with purely axial sites, structural damage to the
hips was also independently associated with worse
Table 2 Multivariable GEE results (adjB; 95% CI) presenting independent associations between BASMI linear (or its compo-
nents) and clinical and demographic variables
Mobility measures where higher











































































































*Statistically significant variables in the univariable analysis but excluded from the best-fit multivariable model;
†Education at baseline (university or equivalent).
‡mSASSS was not significant in the multivariable model but included as it was found to be a contributory variable improving model-fit.
§BASRI-hips was only considered for BASMI linear and for maximal intermalleolar distance.
adjB, adjusted B; ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score C reactive protein; BASMI, Bath Ankylosing Spondylitis
Metrology Index; BASRI-hips, Bath Ankylosing Spondylitis Radiology Index for the hips; BMI, body mass index; cDMARD, conventional
disease-modifying antirheumatic drugs; GEE, generalised estimating equations; HLA-B27, human leucocyte antigen B27; mSASSS, Modified
Stoke Ankylosing Spondylitis Spinal Score; NSAID, nonsteroidal anti-inflammatory drugs; SIJ, sacroiliac joint.
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maximal intermalleolar distance. However, the role of
hip damage in the DESIR cohort is difficult to assess and
may be residual due to the very low levels of hip damage in
this population. Moreover, the sensitivity analysis did not
consider the more peripheral entheses—left and right
anterior superior iliac spine, left and right iliac crest,
and left and right proximal insertion of Achilles tendon
—since the iliac spines and crests are pelvic sites, theymay
theoretically also play a role in hip mobility. While in the
primary analysis the effect of pelvic enthesitis might ‘sur-
pass’ the effect of hip damage, by removing some of the
pelvic entheseal sites from the sensitivity analysis might
Figure 1 Mobility measures (total BASMI score, tragus-to-wall distance, cervical rotation, anterior lumbar flexion (modified
Schöber), lateral spinal flexion and maximal intermalleolar distance) with which each clinical or demographic variable was
independently associated with (range 0–6 mobility measures). ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score
C reactive protein; BASMI, Bath Ankylosing Spondylitis Metrology Index; BASRI-hips, Bath Ankylosing Spondylitis Radi-
ology Index for the hips; BMI, body mass index; HLA-B27, human leucocyte antigen B27; mSASSS, Modified Stoke
Ankylosing Spondylitis Spinal Score.
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have ‘uncovered’ the effect of hip mobility. Finally, in our
study, mSASSS was associated with a measure of lumbar-
thoracic mobility (lateral spinal flexion) but not with
cervical mobility measures. As DESIR is an early disease
population, these results may be explained by the
reported tendency of axSpA to first involve the lower
spine.28
Our study has limitations. The Berlin MRI scoring sys-
tem and the mSASSS do not assess the full spectrum of
MRI or radiographic lesions (eg, inflammation/ankylosis
of the facets joints are not scored and the thoracic spine is
omitted from the mSASSS) and while it can be argued
that these scoring systems can be used as a proxy for
inflammation/damage in these other structures, this lim-
itation may still have an impact, particularly at the indivi-
dual level. MRI inflammation of the hip was also not
assessed and therefore not controlled for in the analyses.
Moreover, despite sites having been instructed with visual
aids and text on how to consistently perform the spinal
mobility assessments, and the existence of a centralised
review process checking for possible inconsistencies (data
quality control), the inter-reader and intra-reader relia-
bility of mobility measures was not assessed in this study.
In conclusion, the current study shows that in an early
axSpA cohort with minimal spinal radiographic damage,
clinical disease activity, measured by ASDAS-CRP, and
active spinal inflammation on MRI are major determi-
nants of spinal mobility impairment. Disease activity is
also associated with hip mobility impairment. Several
other factors influence the degree of both spinal and
hip impairment, namely the severity of enthesitis and
older age, and less so spinal radiographic damage which
may have a more prominent role in later disease stages.
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